Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Yisheng Bio to Collaborate with Scripps Institute on AIDS Vaccine

publication date: Nov 8, 2016
Yisheng Biopharma, a Beijing vaccine company, will collaborate with San Diego's The Scripps Research Institute on a next-gen AIDS vaccine. Yisheng will contribute its PIKA vaccine adjuvant to a TSRI-developed vaccine consisting of novel gp140 trimers and self-assembling nanoparticles. TSRI scientists will also evaluate the potential of PIKA adjuvant for AIDS vaccine candidates. The PIKA adjuvant, a Toll-Like Receptor 3 (TLR3) agonist, has been tested in Phase I clinical trials for hepatitis B and Phase II trials for rabies, with promising results, according to Yisheng. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here